Taro Pharma (TARO) Misses Q4 EPS by 68c
Tweet
Share
E-mailGet Alerts TARO Hot Sheet
Join SI Premium – FREE
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Taro Pharma (NYSE: TARO) reported Q4 EPS of $0.19, $0.68 worse than the analyst estimate of $0.87. Revenue for the quarter came in at $139.2 million versus the consensus estimate of $163.12 million.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Intel pares losses but sheds $9 billion in value on dire outlook, dividend concerns
- Meta (META): Apple's privacy policy change 'no longer a drag on earnings', now a tailwind YoY - WSJ
- Semiconductor market in the middle of fundamental bottoming process - Piper Sandler
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
